Stimulating the Auricular Branch of the Vagus Nerve
Nexeon MedSystems has developed a non-invasive auricular vagus nerve stimulator (aVNS) for the treatment of disease related to neurologic, inflammatory, and metabolic syndrome. Our initial clinical and commercial efforts are in atrial fibrillation (non-valvular paroxysmal) and opioid withdrawal.
Our aVNS device is a non-invasive, battery-powered, self-administered device designed to transcutaneously stimulate the auricular branch of the vagus nerve (ABVN).
The device is worn similar to headphones and is composed of a handheld generator and earpiece. The handheld control unit produces precise, current-controlled stimulation output. Electrical current is delivered through an earpiece with disposable hydrogel electrode contacts to maximize therapeutic potential and minimize the risk of patient discomfort.
Nexeon is pursuing multiple indications for the aVNS technology. Clinical activities are in progress using this technology to treat Atrial Fibrillation and Opioid Withdrawal.
|Opioid withdrawal pilot||Complete 2018|
|Opioid withdrawal pivotal||Complete 2019|
|Opioid FDA approval||2020|
|Atrial fibrillation pilot||Funded, complete in early 2019|
|Atrial fibrillation pivotal||Funded, complete in early 2020|
|Atrial fibrillation CE Mark||2020|